

Reinfection Rate and Its Associated Factors after Two-Stage Revision for Infected Total Knee Arthroplasty

Chang Hyun Nam

Joint & Arthritis Research, Himchan Hospital

Su Chan Lee

Joint & Arthritis Research, Himchan Hospital

Kyungwon Choi

Joint & Arthritis Research, Himchan Hospital

Ji-Hoon Baek (✉ himchanhospital@gmail.com)

Joint & Arthritis Research, Himchan Hospital


Hye Sun Ahn

Joint & Arthritis Research, Himchan Hospital

Research article

Keywords: Two-stage revision, Infected total knee arthroplasty, Recurrence of infection

DOI: <https://doi.org/10.21203/rs.3.rs-157720/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: Two-stage revision is the gold standard for treatment of infected total knee arthroplasty. The purpose of our study was to evaluate the reinfection rate of two-stage revision and to analyze the factors affecting the prognosis of two-stage revision for infected total knee arthroplasty.

Methods: One hundred seven cases of two-stage revision for infected total knee arthroplasty were reviewed retrospectively from March 2006 to November 2019. We evaluated possible risk factors between success and reinfection groups. Statistical analyses included multivariable logistic regression analysis to examine the relative contribution of risk factors to the success of two-stage revision.

Results: There were 19 cases of reinfection (17.8%) after two-stage revision in our center. Between the success and reinfection groups, there was a significant difference in history of cancer ($p=0.015$). Also, multivariable logistic regression analysis of risk factors demonstrated history of cancer (HR 5.928, $p=0.015$). There were no statistically significant differences in reinfection relative to other risk factors.

Conclusions: In subjects undergoing two-stage revision for infected total knee arthroplasty, history of cancer was a risk factor for reinfection, though no other significant differences between risk factors was shown for reinfection.

Trial registration: Retrospectively registered

Level of evidence: IV

Background

Infected total knee arthroplasty (TKA) is the most serious complication of the surgical procedure, and prognosis varies greatly depending on treatment method [1]. This devastating complication is associated with considerable morbidity [2, 3] and economic burden [4]. The incidence of infection following primary TKA ranges from 1–2% [5]. There are various treatment options, including chronic antibiotic suppression [6, 7]; irrigation and debridement (I & D) with component retention [8–13]; one-stage revision [14, 15]; two-stage revision [10, 16–18]; and salvage procedures such as resection arthroplasty, arthrodesis, or amputation [19–23]. Of these treatment options, two-stage revision is considered the gold standard, with a high rate of infection control ranging from 72–100% [24, 25]. However, recurrence of reinfection after two-stage revision occurs in up to 19% of cases [26–28], which elucidates the socioeconomic and individual burden of infected TKA. Previous studies have attempted to identify risk factors associated with reinfection after two-stage revision [29–33]. However, there were no common risk factors among studies. The purpose of the present study was to evaluate the reinfection rate of two-stage revision and to analyze the factors affecting prognosis of two-stage revision for infected TKA.

Methods

The design of this retrospective study was approved by the institutional review board (IRB) at the author's hospital, and all patients provided informed consent.

One hundred forty-two cases (136 patients) of infected TKA from 2008 to 2019 at a single center were reviewed retrospectively. Among these, 35 cases were successfully treated without need for component removal or antibiotic-loaded cement spacer insertion, and four failure cases required two-stage revision after infection control. Therefore, a total of 107 cases (104 patients) of two-stage revision for infected TKA was analyzed including four failure cases (Fig. 1).

The following patient demographics were recorded: age, sex, body mass index (BMI), comorbidities (hypertension, diabetes mellitus (DM), heart disease), previous knee surgery, history of cancer, alcohol drinking, smoking, infection interval, laboratory tests (hemoglobin (Hb), white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)), operation tourniquet time, and type of microorganism.

The types of organisms were 1) methicillin-resistant staphylococci aureus (MRSA); 2) "difficult to treat" (DTT) organisms including quinolone-resistant gram-negative bacteria, rifampicin-resistant *Staphylococcus*, *Enterococcus*, and *Candida*; and 3) all other organism summarized as "easy to treat" (ETT) including anaerobic bacteria, gram-negative bacteria, culture-negative infection, coagulase-negative *Staphylococcus*, polymicrobial infection, staphylococci aureus, and streptococci [34, 35].

The diagnosis of periprosthetic joint infection prior to two-stage revision was confirmed when at least three of the following criteria were met: 1) CRP > 1 mg/dl; 2) ESR > 30 mm/h; 3) positive culture from joint aspirate; 4) pus at operation; and 5) positive intra-operative culture [36].

Two-stage revision consisted of removal of all prosthetic components, insertion of a vancomycin-impregnated cement (2 g vancomycin per 40 g cement) articulating spacer, and delayed reimplantation. After the first stage, patients underwent physiotherapy to encourage passive knee movement and preserve quadriceps strength. Delayed reimplantation was performed when the wound was healthy and the patient was clinically stable with normal CRP. Clinical and radiological data from all patients who underwent joint replacement were collected retrospectively from the joint registries of our institutions. Patients had been examined before surgery and at six weeks, six months, and one year after surgery and yearly thereafter.

Reinfection was diagnosed by clinical signs, blood work (ESR and CRP), and positive culture of synovial aspiration. The mean follow-up period after revision TKA was 62.2 ± 36.9 months. In the reinfection group, 16 patients were females, three patients were male, and the mean age was 70.7 ± 7.8 years. The mean time from revision TKA to diagnosis of reinfection was 15.0 ± 18.8 months. We evaluated possible risk factors between success and reinfection groups.

Differences in continuous variables between the two groups were evaluated using the unpaired t-test or Mann-Whitney rank test. The data are shown as mean \pm standard deviation. For discrete variables, differences are shown as count and percentage and analyzed with the χ^2 outcome (= reinfection) occurred over 15

years of follow-up. Multivariate logistic regression analysis was used to assess the independent impact factor for reinfection. A two-tailed p-value < 0.05 was considered statistically significant.

Results

There were 19 cases of reinfection (17.8%) after two-stage revision in our center. Three patients were treated by I & D, and seven patients underwent a two-stage re-revision TKA. Seven patients who were in poor physical condition or refused additional surgical procedures were treated with antimicrobial therapy, and two cases were lost to follow-up.

The demographic characteristics and univariate analysis of infected TKA patients are shown in Table 1. The mean durations from primary TKA to infection and from infection to implant removal in all patients were 34.3 ± 42.3 months and 20.7 ± 44.5 weeks, respectively.

Table 1
Demographic characteristics of infected total knee arthroplasty patients

Variable	All patients (n = 107)	Reinfection group (n = 19)	Non-reinfection group (n = 88)	p-value
Age at revision TKA (years)*	70.6 ± 6.7	70.7 ± 7.8	70.5 ± 6.5	0.935
Sex†				> 0.999
Male	19 (17.8)	3 (15.8)	16 (18.2)	
Female	88 (82.2)	16 (84.2)	72 (81.8)	
BMI (kg/m ²)*	25.6 ± 3.5	25.4 ± 3.6	25.7 ± 3.4	0.804
Hypertension†	73 (68.2)	15 (78.9)	58 (65.9)	0.268
Diabetes mellitus†	29 (27.1)	6 (31.6)	23 (26.1)	0.628
Heart disease†	3 (2.8)	1 (5.3)	2 (2.3)	0.447
Previous knee surgery†	15 (14.0)	2 (10.5)	13 (14.8)	> 0.999
Cancer†	10 (9.3)	5 (26.3)	5 (5.7)	0.015
Alcohol drinking†	2 (1.9)	0 (0)	2 (2.3)	> 0.999
Smoking†	5 (4.7)	0 (0)	5 (5.7)	0.583
Time from primary TKA to infection (m)*	34.3 ± 42.3	39.3 ± 46.7	33.2 ± 41.5	0.541
Time from infection to implant removal (w)*	20.7 ± 44.5	41.7 ± 47.0	23.0 ± 48.3	0.330
Time from implant removal to revision TKA (w)*	6.2 ± 2.4	6.9 ± 2.5	6.1 ± 2.4	0.197
Time from revision TKA to reinfection (m)*	.	15.0 ± 18.8	.	.
Time from revision TKA to latest follow-up (m)*	61.2 ± 39.1	62.2 ± 36.9	61.0 ± 39.7	0.900
Preoperative primary TKA, CRP*	0.2 ± 0.5	0.25 ± 0.34	0.23 ± 0.58	0.945
Preoperative primary TKA, WBC*	7.6 ± 2.4	7.9 ± 2.4	7.6 ± 2.4	0.684
Preoperative primary TKA, Hb*	13.3 ± 1.3	13.0 ± 1.6	13.4 ± 1.2	0.209
Preoperative primary TKA, ESR*	22.5 ± 18.8	26.3 ± 23.8	21.5 ± 17.4	0.813
Infected TKA, CRP*	8.5 ± 9.2	8.74 ± 7.91	8.45 ± 9.54	0.341
Infected TKA, WBC*	9.8 ± 3.6	9.1 ± 3.3	9.9 ± 3.7	0.289
Infected TKA, Hb*	11.7 ± 1.5	11.4 ± 1.6	11.8 ± 1.5	0.312
Infected TKA, ESR*	69.8 ± 30.9	80.3 ± 29.8	67.1 ± 30.8	0.921
Revision TKA, tourniquet time (m)*	90.0 ± 23.3	88.9 ± 17.4	90.3 ± 24.4	0.851
Type of microorganism†				0.630
MRSA	4 (3.7)	1 (5.3)	3 (3.4)	
DTT	13 (12.1)	3 (15.8)	10 (11.4)	
ETT	90 (84.1)	15 (78.9)	75 (85.2)	
* The values are given as mean and standard deviation.				
† The values are given as number with percentage in parentheses.				
Abbreviations: TKA, total knee arthroplasty; BMI, body mass index; CRP, C-reactive protein; WBC, white blood cell; Hb, hemoglobin; ESR, erythrocyte sedimentation rate; MRSA, methicillin-resistant staphylococci aureus; DTT, difficult to treat; ETT, easy to treat				

The mean time from revision to reinfection in the reinfection group was 15.0 ± 18.8 months. Between the reinfection and success groups, age, sex, and BMI were similar, and there were no significant differences in hypertension, DM, heart disease, previous knee surgery, alcohol drinking, smoking, time from TKA to infection, time from infection to implant removal, time from implant removal to revision interval, time from revision to latest follow up, preoperative primary TKA lab values (CRP, WBC, Hb, and ESR), infected TKA lab values (CRP, WBC, Hb, and ESR), revision TKA tourniquet time, and type of microorganism (MRSA, DTT, and ETT). The only significant difference was history of cancer ($p = 0.015$), which remained significant in multivariable logistic regression analysis (HR 5.928, $p = 0.015$) (Table 2). There were no statistically significant differences in reinfection relative to other risk factors.

Table 2
Multivariable logistic regression analysis of the relative contribution of each variable to reinfection after two-stage revision total knee arthroplasty

Variable	Hazard ratio	95% Confidence interval	p-value
Age at revision TKA (years)*	0.981	0.911–1.055	0.608
Sex, male	0.843	0.219–3.244	> 0.999
BMI (kg/m ²)	0.976	0.842–1.131	0.749
Hypertension	1.939	0.591–6.361	0.268
Diabetes mellitus	1.304	0.443–3.832	0.628
Heart disease	2.388	0.205–27.780	0.447
Previous knee surgery	0.678	0.139–3.292	> 0.999
Cancer	5.928	1.517–23.160	0.015
Alcohol drinking	0.819	0.748–0.896	> 0.999
Smoking	0.813	0.741–0.892	0.583
Time from primary TKA to infection (m)	1.003	0.992–1.014	0.567
Time from infection to implant removal (w)	0.987	0.965–1.010	0.289
Time from implant removal to revision TKA (w)	1.122	0.936–1.345	0.210
Preoperative primary TKA, CRP	0.770	0.171–3.465	0.734
Preoperative primary TKA, WBC	1.037	0.827–1.302	0.748
Preoperative primary TKA, Hb	0.728	0.472–1.122	0.151
Preoperative primary TKA, ESR	0.994	0.957–1.032	0.764
Infected TKA, CRP	1.003	0.951–1.058	0.902
Infected TKA, WBC	0.920	0.783–1.080	0.310
Infected TKA, Hb	0.817	0.578–1.156	0.255
Infected TKA, ESR	1.001	0.984–1.018	0.866
Revision TKA, tourniquet time (m)	0.997	0.976–1.019	0.820
Abbreviations: TKA, total knee arthroplasty; BMI, body mass index; CRP, C-reactive protein; WBC, white blood cell; Hb, hemoglobin; ESR			

In 19 reinfection cases, those with cancer had a final collection period of 3 to 99 months, and those without had a final collection period of 0 to 157 months. There were a total of 10 cancer patients: five were reinfected and five were observed without reinfection. In the reinfection-cancer group, there were two uterine cancers, two gastric cancers, and one colorectal cancer (Table 3).

Table 3
Summary of reinfection after two-stage revision total knee arthroplasty cases

Patient No.	Age at revision TKA /sex	BMI (kg/m ²)	HT/DM/ others	Cancer	Time from primary TKA to infection (m)	Time from infection to implant removal (w)	Time from implant removal to revision TKA (w)	Time from revision TKA to reinfection (m)	Time from revision TKA to latest follow-up (m)	Type of microorganism at infection	Type of microorganism at reinfection
1	61/F	24.5	Yes/Yes/ No	Uterine cancer (TAH)	12	1	7	0	91	No growth	Hafnia
2	71/M	19.5	Yes/No/ Tuberculosis	No	11	1	9	2	122	Staphylococcus aureus	No growth
3	69/F	26.1	Yes/Yes/ Angina	Gastric cancer (subtotal gastrectomy)	27	5	8	1	10	Staphylococcus aureus	No growth
4	64/F	26.6	Yes/No/ Tuberculosis	No	9	12	11	41	123	Coagulase negative Staphylococcus	No growth
5	74/F	24.1	Yes/Yes/ No	No	22	8	7	34	88	No growth	No growth
6	73/M	26.9	Yes/Yes/ No	Colorectal cancer (cured)	3	2	5	43	99	Streptococcus pyogenes	No growth
7	61/F	27.6	No/No/ No	No	3	52	4	0	93	No growth	No growth
8	73/F	25.4	No/No/ No	No	3	40	4	61	91	No growth	No growth
9	75/F	28.8	No/No/ No	No	29	1	4	13	76	No growth	Escherichia coli
10	73/F	18.3	Yes/Yes/ Cerebrovascular accident	No	60	2	6	22	39	Escherichia coli	No growth
11	68/F	29.6	Yes/Yes/ No	No	1	2	10	3	63	No growth	No growth
12	66/F	23.4	Yes/No/ No	No	137	39	4	0	36	No growth	No growth
13	53/F	24.6	No/Yes/ No	No	34	13	7	37	42	Staphylococcus aureus	No growth
14	73/F	27.9	Yes/Yes/ No	No	24	0	5	0	67	Achromobacter xylosoxidans subsp xylosoxidans	No growth
15	63/F	22.2	Yes/Yes/ Cardiac insufficiency	No	141	1	11	5	65	No growth	No growth
16	52/F	32.0	Yes/Yes/ No	No	3	5	6	9	40	Candida albicans	No growth

Abbreviations: TKA, total knee arthroplasty; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; F, female; M, male; TAH, total abdominal hysterectomy; f/u, follow-up

Patient No.	Age at revision TKA /sex	BMI (kg/m ²)	HT/DM/ others	Cancer	Time from primary TKA to infection (m)	Time from infection to implant removal (w)	Time from implant removal to revision TKA (w)	Time from revision TKA to reinfection (m)	Time from revision TKA to latest follow-up (m)	Type of microorganism at infection	Type of microorganism at reinfection
17	71/F	27.4	Yes/No/ No	Uterine cancer (cured)	32	1	5	8	12	No growth	Streptococcus dysgalactiae
18	69/M	19.8	Yes/No/ No	Gastric cancer (subtotal gastrectomy)	129	9	11	6	18	No growth	No growth
19	68/F	27.9	Yes/No/ No	No	66	2	7	1	7	No growth	No growth

Abbreviations: TKA, total knee arthroplasty; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; F, female; M, male; TAH, total abdominal hysterectomy; f/u, follow-up

Figure 2 depicts the cumulative survival rates between the cancer and non-cancer groups during a one-year period. There was a significantly higher chance that subjects in the cancer group were reinfected within one year compared to that in subjects in the non-cancer group (33.3% vs. 7.2%, $p = 0.002$).

Discussion

Infection remains one of the most serious complications of TKA. Two-stage revision is the standard treatment of infected TKA and seems to eradicate infection and provide a functional outcome.

This case-control study aimed to evaluate the reinfection rate of two-stage revision and to analyze the factors affecting prognosis of two-stage revision for infected TKA. The most important finding of our study is that history of cancer was the only risk factor for reinfection after two-stage revision for infected TKA. There was a significantly higher chance that a subject with cancer would be reinfected within one year than a subject without. In our study, there were 19 cases of reinfection (17.8%) after two-stage revision. This is similar to previous studies that showed a 10–12% incidence of reinfection after two-stage revision [31, 37, 38].

Several studies have reported risk factors and reinfection rate of two-stage revision for infected TKA [26, 33, 39–41]. Sabry et al. reported the following as preoperative predictors of failure following two-stage revision: duration of symptoms, time from index surgery, number of previous surgeries, high markers of inflammation levels (CRP, ESR, and peripheral WBC count), lower hemoglobin and hematocrit, need for soft tissue coverage, time to reimplantation, previous infection in the same joint, higher the American society of anesthesiologists (ASA) score, DM, anemia, heart disease, and infection with a gram-negative organism in the absence of malignancy [39]. Kubista et al. reported chronic lymphedema, revision between resection and definitive reimplantation, and intravenously administered cefazolin as the strongest positive predictors of treatment failure [33]. Fashingbauer et al. reported revision during or after a two-stage exchange, number of surgeries, and alcohol abuse as risk factors for recurrence, and that recurrence rates did not differ among organisms [32].

Fehring et al reported repeat two-stage exchange arthroplasty for periprosthetic knee infection is dependent on host grade (Musculoskeletal Infection Society, MSIS) [40]. Also, Vadiet et al found a higher incidence of failure in those patients with poor general health based on MSIS score, inadequate soft tissue envelope and resistant bacteria [41].

Previous studies attempted to identify risk factors associated with reinfection after two-stage revision [29–33]. However, little information is available concerning the prognosis and risk factors in reinfection after two-stage revision for infected TKA. In this study, that undergoing revision operation for infected TKA with history of cancer (10 patients) showed a relatively high re-infection rate of 50% (5 patients).

This study had some limitations. First, it was retrospectively designed and may have introduced bias when data were not accurately reported in the medical chart. In particular, medical history was recorded through patient statements. Second, in the cancer group, we could not assess cancer recurrence or immunosuppressant use during the follow-up period. Third, we could not analyze antibiotics used due to individualization of treatment regimens without a standardized protocol. Fourth, the finding that there was no organism-dependent difference in reinfection after two-stage revision conflicts with the current literature [42–44]. One possible reason for this discrepancy is that our study had an insufficient number of cases to achieve adequate power analyses.

Nevertheless, our study says that history of cancer might be especially important among systemic host compromising factors and significantly higher chance that subjects in the cancer group were reinfected within one year compared to that in subjects in the non-cancer group.

Conclusions

In conclusion, patients with identified history of cancer undergoing revision operation for infected TKA showed worse outcomes. Therefore, staged revision arthroplasty in patients with history of cancer should be closely observed to minimize re-infection, and these patients should be informed of the high probability of infection.

Abbreviations

TKA: total knee arthroplasty; I & D: irrigation and debridement; IRB: institutional review board; BMI: body mass index; DM: diabetes mellitus; Hb: hemoglobin; WBC: white blood cell; ESR: erythrocyte sedimentation rate; ERP: C-reactive protein; MRSA: methicillin-resistant staphylococci aureus; DTT: difficult to treat; ETT: easy to treat; ASA: American society of anesthesiologists; MSIS: musculoskeletal infection society; HT: hypertension; F: female; M: male; TAH: total abdominal hysterectomy; f/u: follow-up

Declarations

Ethics approval and consent to participate: This study was approved by the Institutional Review Board of Himchan hospital. All patients provided written informed consent to use their medical records in advance.

Consent for publication: Authors agree to publication. This manuscript has not been published in any journal

Availability of data and material: All data generated or analysed during this study are included in this published article.

Competing interests: Each author certifies that he or she has no commercial association (eg. consultancies, stock ownership, equity interest, patent, licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.

Funding: Not applicable.

Authors' contributions: Chang Hyun Nam, Ji-Hoon Baek: writing and revision of article. Su Chan Lee, Kyungwon Choi, Hye Sun Ahn: data collection and statistical analysis.

Acknowledgements: This work was supported by our institution. Published with written consent of the patient.

References

1. Fehring TK, Odum S, Griffin WL, Mason JB, Nadaud M. Early failures in total knee arthroplasty. *Clin Orthop Relat Res.* 2001;392:315–8.
2. Darouiche RO. Treatment of infections associated with surgical implants. *N Engl J Med.* 2004;350:1422–9.
3. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. *J Bone Joint Surg Am.* 2005;87:1746–51.
4. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and knee arthroplasty in the United States. *J Arthroplasty.* 2008;23:984–91.
5. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. *Clin Orthop Relat Res.* 2010;468(1):52–6.
6. Garvin KL, Cordero GX. Infected total knee arthroplasty: diagnosis and treatment. *Instr Course Lect.* 2008;57:305–15.
7. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. *J Bone Joint Surg Br.* 2005;87:249–56.
8. Deirmengian C, Greenbaum J, Lotke PA, Booth RE Jr, Lonner JH. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. *J Arthroplasty.* 2003;18:22–6.
9. Hartman MB, Fehring TK, Jordan L, Norton HJ. Periprosthetic knee sepsis. The role of irrigation and debridement. *Clin Orthop Relat Res.* 1991;273:113–8.
10. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. *Clin Microbiol Infect.* 2006;12:433–9.
11. Marculescu CE, Barbari EF, Hanssen AD, Steckelberg JM, Harmsen SW, Mandrekar JN, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. *Clin Infect Dis.* 2006;42:471–8.
12. Mont MA, Waldman B, Banerjee C, Pacheco IH, Hungerford DS. Multiple irrigation, debridement, and retention of components in infected total knee arthroplasty. *J Arthroplasty.* 1997;12:426–33.
13. Schoifet SD, Morrey BF. Treatment of infection after total knee arthroplasty by debridement with retention of the components. *J Bone Joint Surg Am.* 1990;72:1383–90.
14. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. *Instr Course Lect.* 1999;48:111–22.
15. Silva M, Tharani R, Schmalzried TP. Results of direct exchange or debridement of the infected total knee arthroplasty. *Clin Orthop Relat Res.* 2002;404:125–31.
16. Durbhakula SM, Czajka J, Fuchs MD, Uhl RL. Antibiotic-loaded articulating cement spacer in the 2-stage exchange of infected total knee arthroplasty. *J Arthroplasty.* 2004;19:768–74.
17. Haddad FS, Masri BA, Campbell D, McGraw RW, Beauchamp CP, Duncan CP. The PROSTALAC functional spacer in two-stage revision for infected knee replacements. Prosthesis of antibioticloaded acrylic cement. *J Bone Joint Surg Br.* 2000;82:807–12.
18. Pitto RP, Castelli CC, Ferrari R, Munro J. Pre-formed articulating knee spacer in two-stage revision for the infected total knee arthroplasty. *Int Orthop.* 2005;29:305–8.
19. Ellingsen DE, Rand JA. Intramedullary arthrodesis of the knee after failed total knee arthroplasty. *J Bone Joint Surg Am.* 1994;76:870–7.
20. Falahee MH, Matthews LS, Kaufer H. Resection arthroplasty as a salvage procedure for a knee with infection after a total arthroplasty. *J Bone Joint Surg Am.* 1987;69:1013–21.

21. Isiklar ZU, Landon GC, Tullos HS. Amputation after failed total knee arthroplasty. *Clin Orthop Relat Res.* 1994;299:173–8.
22. Leone JM, Hanssen AD. Management of infection at the site of a total knee arthroplasty. *J Bone Joint Surg Am.* 2005;87:2335–48.
23. Wiedel JD. Salvage of infected total knee fusion: the last option. *Clin Orthop Relat Res.* 2002;404:139–42.
24. Lee JK, Choi CH. Two-stage reimplantation in infected total knee arthroplasty using a re-sterilized tibial polyethylene insert and femoral component. *J Arthroplasty.* 2012;27(9):1701–6.
25. Teeny SM, Dorr L, Murata G, Conaty P. Treatment of infected total knee arthroplasty: irrigation and debridement versus two-stage reimplantation. *J Arthroplasty.* 1990;5(1):35–9.
26. Cochran AR, Ong KL, Lau E, Mont MA, Malkani AL. Risk of reinfection after treatment of infected total knee arthroplasty. *J Arthroplasty.* 2016;31:156–61.
27. Yu Q, Luo M, Wu S, Lai A, Sun Y, Hu Q, et al. Comparison of infection eradication rate of using articulating spacers containing bio-inert materials versus all-cement articulating spacers in revision of infected TKA: a systematic review and meta-analysis. *Arch Orthop Trauma Surg.* 2019;139(5):695–707.
28. Akgun D, Muller M, Perka C, Winkler T. An often-unrecognized entity as cause of recurrent infection after successfully treated two-stage exchange arthroplasty: hematogenous infection. *Arch Orthop Trauma Surg.* 2018;138(9):1199–206.
29. Shrader MW, Schall D, Parvizi J, McCarthy JT, Lewallen DG. Total hip arthroplasty in patients with renal failure: a comparison between transplant and dialysis patients. *J Arthroplasty.* 2006;21(3):324–9.
30. Hanssen AD, Trousdale RT, Osmon DR. Patient outcome with reinfection following reimplantation for the infected total knee arthroplasty. *Clin Orthop Relat Res.* 1995;321:55–67.
31. Hanssen AD, Osmon DR. Evaluation of a staging system for infected hip arthroplasty. *Clin Orthop Relat Res.* 2002;403:16–22.
32. Faschingbauer M, Bieger R, Kappe R, Weiner C, Freitag T, Reichel H. Difficult to treat: are there organism-dependent differences and overall risk factors in success rates for two-stage knee revision? *Arch Orthop Trauma Surg.* 2020;140:1595–602.
33. Kubista B, Hartzler RU, Wood CM, Osmon DR, Hanssen AD, Lewallen DG. Reinfection after two-stage revision for periprosthetic infection of total knee arthroplasty. *Int Orthop.* 2012;36(1):65–71.
34. Akgun D, Perka C, Trampuz A, Renz N. Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study. *Arch Orthop Trauma Surg.* 2018;138(5):635–42.
35. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. *FEMS Immunol Med Microbiol.* 2012;65(2):158–68.
36. Parvizi J, Ghanem E, Menashe S, Barrack RL, Bauer TW. Periprosthetic infection: what are the diagnostic challenges? *J Bone Joint Surg Am.* 2006;88:138–47.
37. Azzam K, McHale K, Austin M, Purtill JJ, Parvizi J. Outcome of a second two-stage reimplantation for periprosthetic knee infection. *Clin Orthop Relat Res.* 2009;467(7):1706–14.
38. Jansen E, Huhtala H, Puolakka T, Moilanen T. Risk factors for infection after knee arthroplasty. A register-based analysis of 43,149 cases. *J Bone Joint Surg Am.* 2009;91(1):38–47.
39. Sabry FY, Buller L, Ahmed S, Klika AK, Barsoum WK. Preoperative prediction of failure following two-stage revision for knee prosthetic joint infections. *J Arthroplasty.* 2014;29(1):115–21.
40. Fehring KA, Abdel MP, Ollivier M, Mabry TM, Hanssen AD. Repeat Two-Stage Exchange Arthroplasty for Periprosthetic Knee Infection Is Dependent on Host Grade. *J Bone Joint Surg Am.* 2017;99(1):19–24.
41. Vadiiee I, Backstein DJ. The Effectiveness of Repeat Two-Stage Revision for the Treatment of Recalcitrant Total Knee Arthroplasty Infection. *J Arthroplasty.* 2019;34(2):369–74.
42. Corvec S, Furustrand Tabin U, Betrisey B, Borens O, Trampuz A. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-beta-lactamase-producing *Escherichia coli* in a foreign-body infection model. *Antimicrob Agents Chemother.* 2013;57(3):1421–7.
43. Furustrand Tabin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, et al. Gentamicin improves the activities of daptomycin and vancomycin against *Enterococcus faecalis* in vitro and in an experimental foreign-body infection model. *Antimicrob Agents Chemother.* 2011;55(10):4821–7.
44. Oliva A, Furustrand Tabin U, Maiolo EM, Jeddari S, Betrisey B, Trampuz A. Activities of fosfomycin and rifampin on planktonic and adherent *Enterococcus faecalis* strains in an experimental foreign-body infection model. *Antimicrob Agents Chemother.* 2014;58(3):1284–93.

Figures




Figure 1
Summary of infected total knee arthroplasty




Figure 2
One-year Kaplan-Meier survival analysis of cancer and non-cancer groups after revision total knee arthroplasty